Genmab Announces Multiple Abstracts To Be Presented At The 65th Annual Meeting And Exposition Of The American Society Of Hematology
Portfolio Pulse from Benzinga Newsdesk
Genmab A/S (NASDAQ:GMAB) announced that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody, have been accepted for presentation and publication at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH). The presentations will include data from several trials evaluating the safety and efficacy of epcoritamab as a monotherapy or in combination for the treatment of patients with various lymphoma subtypes. Results from a phase 1/2 trial evaluating GEN3014, an investigational novel human CD38 monoclonal antibody, in patients with relapsed/refractory multiple myeloma will also be presented.
November 02, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab's announcement of multiple abstracts evaluating epcoritamab being accepted for presentation at the ASH meeting could potentially boost investor confidence in the company's research and development capabilities.
The acceptance of multiple abstracts for presentation at a prestigious event like the ASH meeting indicates recognition from the scientific community, which could potentially boost investor confidence in Genmab's research and development capabilities. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100